Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Accenture
Healthtrust
UBS
Johnson and Johnson
Express Scripts
Federal Trade Commission
Harvard Business School
QuintilesIMS

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: RE39820

« Back to Dashboard

Summary for Patent: RE39820
Title:Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Abstract:Compounds of the formula ##STR00001## of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3.alpha.-(6.beta., 7.beta.-epoxy)-tropanyl methobromide and R.sub.1 is 2-thienyl; (b) A is 3.alpha.-(6, 7dehydro)-tropanyl methobromide and R.sub.1 is 2-thienyl; (c) A is 3.beta.-tropanyl methobromide and R.sub.1 is 2-thienyl; and, (d) A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide and R.sub.1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Inventor(s): Banholzer; Rolf (Stuttgart, DE), Bauer; Rudolf (Ockenheim, DE), Reichl; Richard (Gau-Algesheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:11/254,213
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Dosage form;

Drugs Protected by US Patent RE39820

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim STIOLTO RESPIMAT olodaterol hydrochloride; tiotropium bromide SPRAY, METERED;INHALATION 206756-001 May 21, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF COPD ➤ Subscribe
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-002 Sep 15, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-001 Sep 24, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE39820

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany39 31 041.8Sep 16, 1989
PCT/EP90/01517Sep 08, 1990
PCT/EP90/01517Sep 8, 1990

Non-Orange Book US Patents Family Members for Patent RE39820

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,610,163 Esters of thienyl carboxylic acids and amino alcohols and their quaternization products ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE39820

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Fuji
Harvard Business School
McKesson
Merck
Covington
Novartis
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot